Live
- CM Revanth Reddy to Attend Commonwealth Mediation and Arbitration Conference Today
- Beware of new cyber scam ‘digital arrest’: SP Subba Rayudu
- Sensex, Nifty slip under pressure amid weak global cues
- Posters on novel solutions to problems at Tech Summit
- Conduct Tiruchanoor fest akin to Tirumala’s: TTD EO
- Allocate Khelo India funds for sports infra in SVU
- BJP stages protests in various dists over alleged Waqf encroachments
- CM defends BPL ration card cancellation
- Industry should make use of Rs 1-trn ANRF fund: Goyal
- TTD chairman meets Telangana CM
Hyderabad: Covaxin clinical trails for children underway
(Picture used for representational purpose only)
Clinical trails are underway for Covaxin for the children between two and 18 years of age by the Bharat Biotech. Also, a clinical trial to learn the safety and immunogenicity of a booster dose is also in process.
Clinical trails are underway for Covaxin for the children between two and 18 years of age by the Bharat Biotech. Also, a clinical trial to learn the safety and immunogenicity of a booster dose is also in process.
The company said that they are carrying out the experiments on the variants of virus and assess their suitability for follow-up booster doses.
Bharath Biotech developed Covaxin received Emergency Use Authorizations (EUA) in 16 countries including, Brazil, India, Philippines, Iran, Mexico, etc. The company is in talks with WHO to obtain Emergency Use Listing (EUL) for Covaxin. The product has been exported to several countries, with additional requests for supplies being received.
At present, there are four facilities of Bharat Biotech within India, and further expansion is in process by the end of 2021.
